Prescriber:
To initiate a free 1-month trial supply for an appropriate
patient, you should:
- Write a prescription for up to 30 tablets or packs of oral granules of SINGULAIR. Not valid for refills. No substitutions are permitted.
- Select the appropriate check box on the voucher.
- Give the valid signed prescription and voucher to the patient. Eligible patients can take the voucher and the prescription to any participating eligible retail pharmacy to receive their free 1-month trial supply.
- If you want your patient to continue taking SINGULAIR beyond the free trial period, you must write a separate prescription based on your recommended therapy.
- For a copy of the Prescribing Information, call 800-672-6372, visit singulair.com, or contact your Merck representative.
- Expiration Date: 02/28/2011.
Terms and Conditions
- The voucher is valid for 1 free 1-month trial supply of SINGULAIR.
- Limit 1 voucher per patient for the duration of the program. Valid for 1-time use only. Free trial offer valid only for up to 30 tablets or packs of oral granules of SINGULAIR. No purchase is necessary. Not valid for refills.
- The voucher is not transferable. No substitutions are permitted. Cannot be combined with any other free trial, coupon, discount, prescription savings card, or other offer.
- The voucher is not insurance.
- For patients younger than 18 years who are prescribed SINGULAIR, voucher can be used by parent or guardian.
- Patient, guardian, and prescriber agree not to seek reimbursement for all or any part of the benefit received by the patient through this offer.
- The voucher can be used only by eligible US residents at participating eligible retail pharmacies in the United States. Product must originate in the United States.
- It is illegal to sell, purchase, trade, or counterfeit the voucher.
- The voucher is the property of Merck and must be turned in on request.
- Merck reserves the right to rescind, revoke, or amend this offer at any time without notice.
- Void if reproduced. Void where prohibited by law, taxed, or restricted.
- Expiration Date: 02/28/2011.
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.
For prevention of EIB, a single dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.
Patients already taking 1 tablet daily for another indication should not take an additional dose to prevent EIB.
SELECTED SAFETY INFORMATION
- SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
- Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
- Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
- Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.
Before prescribing SINGULAIR, please read the Prescribing Information.
For general information and other services for physicians
SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
PRIVACY POLICY